Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing
Details : Third Pole's technology generates pure inhaled nitric oxide (iNO) for therapeutic use and delivers it to the patient on demand, providing clinicians with greater flexibility than with iNO therapeutics stored in compressed gas cylinders.
Product Name : eNOfit
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beyond Air to Participate in Three Upcoming Medical Conferences
Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in human body, proven to play a critical role in a broad array of biological functions. In airways, NO targets vascular smooth muscle cells that surround small resistance arteries in lungs.
Product Name : LungFit PRO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration sets forth the framework by which both companies will work together to develop a new nebulized LABA/LAMA combination formulation for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Richard King Mellon Foundation
Deal Size : $0.2 million
Deal Type : Funding
Details : The funding will support pivotal/Phase III cellular therapy study that uses an intravenous injection of autologous stromal vascular fraction (SVF) cells, derived at point-of-care using the GID BIO SVF-2 technology platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Richard King Mellon Foundation
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Novellus, a Cambridge, Mass-based cell engineering company, has developed patented, non-immunogenic mRNA-based induced mesenchymal stem cell (iMSC) platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : ILC Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaborative work between ILC Therapeutics and Dr. Catherine Adamson from the School of Biology at the University of St Andrews, will focus on the role that Alfacyte can play in preventing COVID-19-indusced acute respiratory distress syndrome (ARDS)...
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Undisclosed
June 23, 2020
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : ILC Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : BXT-25
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus
Details : Bioxytran seeks to explore collaborations with international drug makers to treat patients at the end stage of Acute Respiratory Distress Syndrome affected with Wuhan Coronavirus.
Product Name : BXT-25
Product Type : Protein
Upfront Cash : Undisclosed
May 02, 2020
Lead Product(s) : BXT-25
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership